EFCAB14

Across TCGA pan-cancer cohorts, EFCAB14 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EFCAB14 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EFCAB14 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EFCAB14 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where EFCAB14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.377	0.723	.003	19	view →
HNSC	OS	Quartile	III,IV	1.000	0.330	.036	9	view →
LUAD	OS	Median	II,III,IV	1.000	0.433	.005	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EFCAB14–PDAC (OS)

Open the PDAC breakdown →